Insights in Genetic Medicine

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2356

Special Issue Editor


E-Mail Website
Guest Editor
División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico
Interests: cancer; variants; polymorphism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of illness and death worldwide. Different clinical, epidemiological, and molecular studies have shown advances in the basic knowledge of the biology of cancer, its diagnosis, and treatment. In this sense, the advances in knowledge of the variants in different metabolic pathways that participate in the processes and susceptibility to the development of cancer have been of great importance. Thus, it has been observed that the frequency of these variants depends to a large extent on the study population, so it is interesting to know data specific to each region. In Mexico, breast, colon, and lung cancer are among the main causes of death, which is why our group is interested in the great diversity of genes that participate in the evolution of cancer, as well as in its treatment. Among the genes that have attracted attention are, for example, the KRAS, ESR1, ESR2, ERBB2, TNF alpha, VEGF, eNOS, Tp53, RAD1, MTHFR, CBS, and TYMS genes.

Dr. Martha Patricia Gallegos-Arreola
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • variants
  • breast cancer
  • colorectal cancer
  • lung cancer
  • polymorphism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2654 KiB  
Article
Association of the rs8720 and rs12587 KRAS Gene Variants with Colorectal Cancer in a Mexican Population and Their Analysis In Silico
by Martha Patricia Gallegos-Arreola, Asbiel Felipe Garibaldi-Ríos, José Israel Cruz-Sánchez, Luis Eduardo Figuera, Carlos Alberto Ronquillo-Carreón, Mónica Alejandra Rosales-Reynoso, Belinda Claudia Gómez-Meda, Irving Alejandro Carrillo-Dávila, Ana María Puebla-Pérez, Héctor Montoya-Fuentes, Valeria Peralta-Leal and Guillermo M. Zúñiga-González
Cells 2023, 12(15), 1941; https://doi.org/10.3390/cells12151941 - 26 Jul 2023
Cited by 1 | Viewed by 1929
Abstract
Colorectal cancer (CRC) is a major global health challenge and one of the top 10 cancers in Mexico. Lifestyle and genetic factors influence CRC development, prognosis, and therapeutic response; identifying risk factors, such as the genes involved, is critical to understanding its behavior, [...] Read more.
Colorectal cancer (CRC) is a major global health challenge and one of the top 10 cancers in Mexico. Lifestyle and genetic factors influence CRC development, prognosis, and therapeutic response; identifying risk factors, such as the genes involved, is critical to understanding its behavior, mechanisms, and prognosis. The association between KRAS gene variants (rs8720 and rs12587) and CRC in the Mexican population was analyzed. We performed in silico analysis and analyzed 310 healthy individuals and 385 CRC patients using TaqMan assays and real-time PCR. The CC and GG genotypes of rs8720 and rs12587 were identified as CRC risk factors (p < 0.05). The CC and TC genotypes of the rs8720 were associated with rectal cancer, age over 50 years, moderately differentiated histology, and advanced cancer stage. TG and GG genotypes of the rs12587 variant were a risk factor in the CRC group, in patients with stage I–II, males, and stage III–IV non-chemotherapy response. The TG haplotype is protected against CRC. The combined CCGG genotype was linked to CRC risk. In silico analysis revealed that the rs12587 and rs8720 variants could influence KRAS gene regulation via miRNAs. In conclusion, rs8720 and rs12587 variants of the KRAS gene were associated with CRC risk and could influence KRAS regulation via miRNAs. Full article
(This article belongs to the Special Issue Insights in Genetic Medicine)
Show Figures

Figure 1

Back to TopTop